Cited by 2,218Cancer Genomics and DiagnosticsBRCA gene mutations in cancerChromatin Remodeling and Cancer

Landscape of somatic mutations in 560 breast cancer whole-genome sequences

Open access
Nik-Zainal, Serena, Davies, Helen, Staaf, Johan, Ramakrishna, Manasa, Glodzik, Dominik, Zou, Xueqing, Martincorena, Inigo, Alexandrov, Ludmil B. +80 more·2016·Nature

Abstract

We analysed whole-genome sequences of 560 breast cancers to advance understanding of the driver mutations conferring clonal advantage and the mutational processes generating somatic mutations. We found that 93 protein-coding cancer genes carried probable driver mutations. Some non-coding regions exhibited high mutation frequencies, but most have distinctive structural features probably causing elevated mutation rates and do not contain driver mutations. Mutational signature analysis was extended to genome rearrangements and revealed twelve base substitution and six rearrangement signatures. Three rearrangement signatures, characterized by tandem duplications or deletions, appear associated with defective homologous-recombination-based DNA repair: one with deficient BRCA1 function, another with deficient BRCA1 or BRCA2 function, the cause of the third is unknown. This analysis of all classes of somatic mutation across exons, introns and intergenic regions highlights the repertoire of cancer genes and mutational processes operating, and progresses towards a comprehensive account of the somatic genetic basis of breast cancer. Whole-genome sequencing of tumours from 560 breast cancer cases provides a comprehensive genome-wide view of recurrent somatic mutations and mutation frequencies across both protein coding and non-coding regions; several mutational signatures in these cancer genomes are associated with BRCA1 or BRCA2 function and defective homologous-recombination-based DNA repair. This study reports whole-genome sequencing of tumours and normal tissue from 560 breast cancer cases, providing a comprehensive genome-wide view of recurrent somatic mutations and mutation frequencies across both protein coding and non-coding regions. The authors analyse mutational signatures in these cancer genomes, including a new investigation of rearrangement mutational processes, and find several that are associated with BRCA1 or BRCA2 function and defective homologous-recombination-based DNA repair. They also find mutational signatures showing distinct DNA replication strand biases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/nature17676

Cites

60 of 60 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • BRCA inactivation promotes genomic instability through homologous recombination deficiencies in several solid tumors such as breast and ovarian cancer.

    “For example, BRCA inactivation is known to promote genomic instability through homologous recombination deficiencies in several solid tumors such as breast and ovarian cancer.47”

    From Evolution of Multiple Myeloma from a Genomic Perspective (2026) · cites this paper as [47]

    The Results section, “Mutational signatures associated with BRCA1 and BRCA2 mutations” (page not provided), links BRCA1/2 inactivation in breast cancers to numerous genomic rearrangements and discusses defective homologous-recombination repair. The study does not establish the same relationship in ovarian cancer or across several solid tumor types; ovarian cancer appears only in a cited reference. (LLM, conf=0.88)

    Experimental — accuracy not yet measured
  • Some mutational footprints are associated with BRCA1/2 deficiency, namely deletions with flanking microhomology and several mutational signatures including two COSMIC SNV signatures and two SV signatures.

    “Indeed, some mutational footprints were found to be associated with BRCA1/2 deficiency, namely deletions with flanking microhomology, as well as several “mutational signatures” including two COSMIC single nucleotide variant (SNV) signatures and two structural variant (SV) signatures8.”
  • Genomic features in the SCAN-B TNBC cohort were comparable to a previously reported WGS cohort.

    “These genomic features in the SCAN-B TNBC cohort were comparable to a previously reported WGS cohort8”
  • Five substitution signatures and five rearrangement signatures were detected.

    “Five substitution and five rearrangement signatures [8, 9] were identified”
  • In the cohort, 79 of the 93 previously reported breast cancer driver genes carried mutations.

    “Seventy-nine out of the 93 previously identified BC driver genes [9] were mutated”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Nik-Zainal, S., Davies, H., Staaf, J., Ramakrishna, M., Glodzik, D., Zou, X., Martincorena, I., Alexandrov, L. B., Martin, S., Wedge, D. C., Van Loo, P., Ju, Y. S., Smid, M., Brinkman, A. B., Morganella, S., Aure, M. R., Lingjærde, O. C., Langerød, A., Ringnér, M., Ahn, S.-M., Boyault, S., Brock, J. E., Broeks, A., Butler, A., Desmedt, C., Dirix, L., Dronov, S., Fatima, A., Foekens, J. A., Gerstung, M., Hooijer, G. K. J., Jang, S. J., Jones, D. R., Kim, H.-Y., King, T. A., Krishnamurthy, S., Lee, H. J., Lee, J.-Y., Li, Y., McLaren, S., Menzies, A., Mustonen, V., O’Meara, S., Pauporté, I., Pivot, X., Purdie, C. A., Raine, K., Ramakrishnan, K., Rodríguez-González, F. G., Romieu, G., Sieuwerts, A. M., Simpson, P. T., Shepherd, R., Stebbings, L., Stefansson, O. A., Teague, J., Tommasi, S., Treilleux, I., Van den Eynden, G. G., Vermeulen, P., Vincent-Salomon, A., Yates, L., Caldas, C., Veer, L. V., Tutt, A., Knappskog, S., Tan, B. K. T., Jonkers, J., Borg, Å., Ueno, N. T., Sotiriou, C., Viari, A., Futreal, P. A., Campbell, P. J., Span, P. N., Van Laere, S., Lakhani, S. R., Eyfjord, J. E., Thompson, A. M., Birney, E., Stunnenberg, H. G., van de Vijver, M. J., Martens, J. W. M., Børresen-Dale, A.-L., Richardson, A. L., Kong, G., Thomas, G., & Stratton, M. R.
Affiliations
  • Wellcome Sanger Institute (GB)
  • Lund University (SE)
  • Los Alamos National Laboratory (US)
  • Erasmus MC (NL)
  • Radboud University Nijmegen (NL)
  • European Bioinformatics Institute (GB)
  • Oslo University Hospital (NO)
  • University of Oslo (NO)
  • Gachon University Gil Medical Center (KR)
  • Centre Léon Bérard (FR)
  • Brigham and Women's Hospital (US)
  • The Netherlands Cancer Institute (NL)
  • Université Libre de Bruxelles (BE)
  • University of Antwerp (BE)
  • Dana-Farber Cancer Institute (US)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Asan Medical Center (KR)
  • Hanyang University (KR)
  • Memorial Sloan Kettering Cancer Center (US)
  • The University of Texas MD Anderson Cancer Center (US)
  • Institut National du Cancer (FR)
  • Inserm (FR)
  • Ninewells Hospital (GB)
  • Institut Regional du Cancer de Montpellier (FR)
  • The University of Queensland (AU)
  • Istituto Tumori Bari (IT)
  • University of Cambridge (GB)
  • Institute of Cancer Research (GB)
  • Haukeland University Hospital (NO)
  • Singapore General Hospital (SG)
  • Institut national de recherche en sciences et technologies du numérique (FR)
  • Radboud University Medical Center (NL)
  • University of Iceland (IS)
Corresponding author
  • Viari, Alain
  • Kong, Gu
  • Stratton, Michael R.
Venue
Nature
Published
2016-05-02
Volume
534
Issue
7605
Pages
47-54
ISSN
  • 0028-0836 (ISSN-L)
  • 1476-4687
OpenAlex
W2344657883
Cited by
2,218
References
60
Citations by year
2026: 125 · 2025: 147 · 2024: 178 · 2023: 271 · 2022: 212 · 2021: 293 · 2020: 288 · 2019: 241 · 2018: 200 · 2017: 181 · 2016: 78 · 2015: 1 · 2014: 1
FWCI
97.22
Type
journal article
Language
en
Open access
Locations
  • Nature (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
  • Pure Amsterdam UMC (acceptedVersion, other-oa)
  • PubMed Central (acceptedVersion)
  • Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
  • OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) (submittedVersion)
  • Apollo (University of Cambridge) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • RePEc: Research Papers in Economics (submittedVersion)
  • Discovery Research Portal (University of Dundee) (submittedVersion)
  • Figshare (submittedVersion, cc-by)
  • Research Portal (King's College London) (submittedVersion)
  • Lirias (KU Leuven) (submittedVersion)
  • Lund University Publications (Lund University) (submittedVersion)
  • Radboud Repository (Radboud University) (submittedVersion)
  • RePub (Erasmus University Rotterdam) (submittedVersion)
  • Apollo
Funders
  • U.S. Department of Energy (DE-AC52-06NA2-5396, AC52-06NA25396)
  • Breast Cancer Research Foundation
  • Dana-Farber/Harvard Cancer Center (P50 CA168504)
  • University of Dundee
  • Wellcome Trust (088177, 077012/Z/05/Z, 100183, 077012, WT100183MA, 098051)
  • Francis Crick Institute (10202)
  • QIMR Berghofer Medical Research Institute
  • Cancer Research UK (60098573, 20952, CB4140, 16942)
  • National Institute for Health and Care Research (NF-SI-0515-10090, NF-SI-0611-10154)
  • Breast Cancer Campaign
  • University of Cambridge
  • European Commission (242006)
  • National Research Foundation
  • Icelandic Centre for Research
  • Fonds De La Recherche Scientifique - FNRS
  • Cancerfonden
  • Cambridge University Hospitals (RG51913)
  • Nederlandse Organisatie voor Wetenschappelijk Onderzoek
  • National Research Foundation of Korea (2015R1A2A1A10052578, 2011-0030105)
  • Vetenskapsrådet
  • Háskóli Íslands
  • Institut National Du Cancer
  • Rannís
  • National Institutes of Health (DE-AC52-06NA25396)
  • National Nuclear Security Administration (DEAC52- 06NA25396)
  • National Cancer Institute (CA168504, P30CA008748, P50CA168504)
  • Los Alamos National Laboratory (AC52-06NA25396, DE-AC52-06NA25396)
  • FP7 Ideas: European Research Council (322737)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
Keywords
breast cancer, somatic mutations, driver mutations, mutational signatures, tandem duplication, homologous recombination deficiency, BRCA1, BRCA2, non-coding regions, intronic variants
MeSH terms
Breast Neoplasms, DNA Mutational Analysis, DNA Replication, DNA, Neoplasm, Female, Humans, Male, Mutation, Oncogenes, Cohort Studies, Genome, Human, Mutagenesis, Genes, BRCA1, Genomics, Genes, BRCA2, Mutation Rate, Recombinational DNA Repair

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review